Clinical Trials Browser

Terminated × oblimersen × Clear all

NCT00736450 2023-10-24

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase EARLY_PHASE1 Terminated

37 enrolled 8 charts

Lymphoma, Large B-Cell, Diffuse

NCT00064259 2021-02-17

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Phase 1/2 Terminated

15 enrolled 5 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT00063934 2019-03-05

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

31 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01200342 2016-02-11

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Phase 2 Terminated

7 enrolled 3 charts

Uveal Melanoma, Melanoma

NCT00091078 2013-06-05

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Phase 2 Terminated

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00060112 2013-01-25

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Phase 1 Terminated

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00080847 2013-01-07

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2 Terminated

Lymphoma, Large B-Cell, Diffuse

NCT00301795 2013-01-07

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 2 Terminated

Lymphoma, Follicular